Association between combined treatment with SGLT2 inhibitors and metformin for type 2 diabetes mellitus on fracture risk: a meta-analysis of randomized controlled trials
The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
This study analyzed the effects of combination therapy with sodium-glucose transporter-2 inhibitors (SGLT2is) and metformin on fracture risk. Summarizing available randomized controlled trials, we found that SGLT2is combined with metformin therapy did not influence fracture risk compared with metformin monotherapy or other comparators in patients with T2DM. Introduction No study is available evaluating the association between sodium-glucose transporter-2 inhibitors (SGLT2is) in combination with metformin use and fracture risk. Our study aimed to investigate the fracture risk of combination therapy with SGLT2is and metformin in patients with type 2 diabetes mellitus (T2DM). Methods PubMed, Embase, ClinicalTrials.gov site, and the Cochrane Library databases were scrutinized for all eligible randomized controlled trials (RCTs). The summarized odds ratios (ORs) and their 95% confidence intervals (CI) were calculated using Review Manager 5.3 software. Results A total of 25 RCTs involving 19,500 participants with T2DM were included in our studies. There were 88 fracture cases in the SGLT2is in combination with metformin therapy group and 79 in the control group. SGLT2is combined with metformin use did not influence fracture risk compared with metformin monotherapy or other comparators in patients with T2DM (OR = 0.97, 95% CI 0.71-1.32). After stratification by drug type, follow-up time, control regimen, and type of fracture, the upshots were still stable. Conclusion SGLT2is and met…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“While early studies brought attention to several safety areas of interest (acute kidney injury, dehydration, orthostatic hypotension, amputation, and fractures) (5,6), longer-term studies that have prospectively assessed and monitored these events (160,161) have not seen a signi fi cant imbalance in risks.”
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Saeedi, P., Petersohn, I., Salpea, P., Malanda, B., Karuranga, S., Unwin, N., Colagiuri, S., Guariguata, L., Motala, A. A., Ogurtsova, K., et al. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107843 · Cited by 10,792
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830 · cited 2×
“Also, the CANagliflozin cardioVascular Assessment Study (CANVAS) Program [20] suggested a higher incidence of fracture in the canagliflozin group compared with the placebo group.”
BackgroundCanagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189 · cited 1×
“Canagliflozin was associated with increased fracture risk in CANVAS, while no increase in fracture risk observed in CANVAS-Renal (CANVAS-R), and the recently reported CREDENCE (Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation) trial [20, 27].”
BackgroundZelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Furtado, R. H. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32590-x · Cited by 2,845
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetologia · doi:10.1007/s00125-018-4729-5 · Cited by 1,455
Buse, J. B., Wexler, D. J., Tsapas, A., Rossing, P., Mingrone, G., Mathieu, C., D’Alessio, D. A., & Davies, M. J. (2020) · Diabetes Care · doi:10.2337/dci19-0066 · Cited by 1,192
Mechanisms of diabetes mellitus-induced bone fragility
On behalf of the IOF Bone and Diabetes Working Group, Napoli, N., Chandran, M., Pierroz, D. D., Abrahamsen, B., Schwartz, A. V., & Ferrari, S. L. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.153 · Cited by 1,107 · cited 1×
“Previous researches have illustrated that the negative impacts of T2DM on bone may be multifactorial, consisting of things such as hyperglycemia, oxidative stress, toxic effects of advanced glycosylation endproducts (AGEs), altered insulin levels, and treatmentinduced hypoglycemia and increased propensity for falls, a…”
Background9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s009 · Cited by 914
Kohan, D. E., Fioretto, P., Tang, W., & List, J. F. (2014) · Kidney International · doi:10.1038/ki.2013.356 · Cited by 652
Cited by
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetes Care · doi:10.2337/dci22-0034 · Cited by 2,104
“While early studies brought attention to several safety areas of interest (acute kidney injury, dehydration, orthostatic hypotension, amputation, and fractures) (5,6), longer-term studies that have prospectively assessed and monitored these events (160,161) have not seen a significant imbalance in risks.”
BackgroundDavies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetologia · doi:10.1007/s00125-022-05787-2 · Cited by 1,048
“While early studies brought attention to several safety areas of interest (acute kidney injury, dehydration, orthostatic hypotension, amputation and fractures) [5, 6], longer-term studies that have prospectively assessed and monitored these events [160, 161] have not seen a significant imbalance in risks.”
Chai, S., Liu, F., Yang, Z., Yu, S., Liu, Z., Yang, Q., & Sun, F. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.825417 · Cited by 44
“A lot of research in this field has been carried out, and there are studies which reported the effects of different hypoglycemic drugs on fracture risk in T2DM (Lee et al., 2019; Salari-Moghaddam et al., 2019; Qian et al., 2020; Zhang et al., 2020).”
BackgroundCareful use to minimize adverse events of oral antidiabetic medications in the elderly
Scheen, A. J. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1912735 · Cited by 37
Fracture Risk of Sodium-Glucose Cotransporter-2 Inhibitors in Chronic Kidney Disease
Cowan, A., Jeyakumar, N., Kang, Y., Dixon, S. N., Garg, A. X., Naylor, K. L., Weir, M. A., & Clemens, K. K. (2022) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.16171221 · Cited by 37
Metadata
- Authors
- Qian, B.-B., Chen, Q., Li, L., & Yan, C.-F.
- Affiliations
- Dalian Medical University (CN)
- Venue
- Osteoporosis International
- Published
- 2020-08-11
- Volume
- 31
- Issue
- 12
- Pages
- 2313-2320
- ISSN
- 0937-941X (ISSN-L)
- 1433-2965
- OpenAlex
- W3048607731
- Cited by
- 22
- References
- 43
- Citations by year
- 2026: 3 · 2025: 1 · 2024: 2 · 2023: 7 · 2022: 6 · 2021: 3
- FWCI
- 0.61
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Osteoporosis International (publishedVersion)
- PubMed (publishedVersion)
- Funders
- The Social Development Foundation of Yangzhou City of China (YZ2016061)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- SGLT2 inhibitors, metformin, combination therapy, fracture risk, type 2 diabetes, osteoporosis, antidiabetic drugs
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Metformin, Randomized Controlled Trials as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Association between combined treatment with SGLT2 inhibitors and metformin for type 2 diabetes mellitus on fracture risk: a meta-analysis of randomized controlled trials. https://app.cochat.ai/papers/10.1007/s00198-020-05590-y
- The paper
- Qian, B.-B., Chen, Q., Li, L., & Yan, C.-F. (2020). Association between combined treatment with SGLT2 inhibitors and metformin for type 2 diabetes mellitus on fracture risk: a meta-analysis of randomized controlled trials. Osteoporosis International. https://doi.org/10.1007/s00198-020-05590-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.